Content verification of the EORTC QLQ-C30/EORTC QLQ-BR23 with the International Classification of Functioning, Disability and Health

Letellier, Marie-Eve; Dawes, Diana; Mayo, Nancy E.

doi:10.1007/s11136-014-0791-8

Cited by 26 publications

(20 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While we did not include this 30-item measure, its content has been shown to capture 25 domains related to symptoms and function and also includes three questions, one each on health perception, overall QOL rating, and financial impact of cancer [55]. The functional domains on the EORTC Fig.…”

Section: Discussionmentioning

confidence: 99%

Using a personalized measure (Patient Generated Index (PGI)) to identify what matters to people with cancer

Aburub

Gagnon

Rodríguez

et al. 2015

Support Care Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Using a personalized measure (Patient Generated Index (PGI)) to identify what matters to people with cancer

Aburub

Gagnon

Rodríguez

et al. 2015

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…The adverse events were graded based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 . QOL was evaluated using the European Organization for Research and Treatment of Cancer Quality of Life of Questionnaire (EORTC QLQC30) questionnaire at study entry, and prior to surgery . In addition, the parameters of tumor metabolism and blood supply, as demonstrated by PET and DCE‐MRI, were collected and analyzed.…”

Section: Methodsmentioning

confidence: 99%

A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first‐line therapy for patients with breast cancer (CBCRT01)

Chen

Yao

Huang

et al. 2017

Intl Journal of Cancer

View full text Add to dashboard Cite

To further assess the efficacy and safety of recombinant human endostatin (rh-endostatin), a Phase III, multicenter, prospective, randomized, controlled clinical trial was conducted. Patients to be treated with neoadjuvant docetaxel and epirubicin (DE) or DE plus rh-endostatin (DEE) were eligible for this trial. The primary endpoint was clinical/pathological response. Secondary endpoints included adverse events and quality of life (QOL). Finally, 803 patients were enrolled and randomly assigned to receive DE (n = 402) or DEE (n = 401) regimen. After three cycles of neoadjuvant therapy, "complete response" achieved in 14.2% of patients in DEE group versus 6.7% in DE group, "partial response" achieved in 76.8% versus 71.1%, while "stable disease" in 6.0% versus 18.9%, "progressive disease" in 3.0% versus 3.2% of patients. The rate of objective response in DEE and DE group was 91.0% and 77.9%, respectively (p < 0.001). In spite of a relatively higher pathological complete response achieved following the combination therapy, no significant difference was found between two arms. Adverse events were mostly of Grades 1-2. No significant difference in adverse event and QOL was found between the two arms. In conclusion, the combination of chemotherapy and rh-endostatin achieved better outcomes than chemotherapy alone, and thus can be considered as a promising therapeutic strategy for breast cancer.

show abstract

“…One study 40 assessed the content validity of the EORTC QLQ-C30 based on the opinions of 21 experts. When mapping to the WHO's International Classification of Functioning (ICF) framework, 25 of the 30 items in the EORTC QLQ-C30 were endorsed by the experts: 15 items mapping to impairment of body function, 7 mapping to activity limitations/participation restrictions, and 1 item mapping to both components.…”

Section: Assessment Of Validity Reliability and Responsivenessmentioning

confidence: 99%

“…The authors stated that the fact that most items from the EORTC QLQ-C30 can be linked to the ICF framework means that the instrument's content reflects functioning, which is a key component of HRQoL. 40 No studies were identified that investigated the validity, reliability, or responsiveness of the EORTC QLQ-C30 among patients with earlystage TNBC. Among patients with metastatic breast cancer, a 1997 study investigated the inter-rater reliability using patient-observer agreement on the EORTC QLQ-C30 questionnaire.…”

Section: Assessment Of Validity Reliability and Responsivenessmentioning

confidence: 99%

Pembrolizumab (Keytruda)

CADTH¹

2022

cjht

View full text Add to dashboard Cite

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses pembrolizumab (Keytruda), 200 mg IV every 3 weeks or 400 mg IV every 6 weeks. Indication: For the treatment of adult patients with high-risk, early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery.

show abstract

Content verification of the EORTC QLQ-C30/EORTC QLQ-BR23 with the International Classification of Functioning, Disability and Health

Cited by 26 publications

References 35 publications

Using a personalized measure (Patient Generated Index (PGI)) to identify what matters to people with cancer

Using a personalized measure (Patient Generated Index (PGI)) to identify what matters to people with cancer

A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first‐line therapy for patients with breast cancer (CBCRT01)

Pembrolizumab (Keytruda)

Contact Info

Product

Resources

About